Tag Archives: Virus

Members of the Flavivirus Genus With Known Arthropod Vectors

http://labmed.oxfordjournals.org/content/40/8/493

Group Classification Vector Species
Mammalian Tick Gadgets Gully virus
Kadam virus
Kyasanur Forest disease virus
Langat virus
Louping ill virus
Omsk hemorrhagic fever virus Powassan virus
Royal Farm virus
Tick-borne encephalitis virus
Seabird Tick Meaban virus
Saumarez Reef virus
Tyuleniy virus
Aroa Mosquito Aroa virus
Dengue Mosquito Dengue virus
Kedougou virus
Japanese encephalitis Mosquito Cacipacore virus
Japanese encephalitis virus
Koutango virus
Murray Valley encephalitis virus
St. Louis encephalitis virus
Usutu virus
West Nile virus
Yaounde virus
Kokobera Mosquito Kokobera virus
Ntaya Mosquito Bagaza virus
Ilheus virus
Israel turkey virus§ Ntaya virus
Tembusu virus
Spondweni Mosquito Zika virus
Yellow fever Mosquito Banzi virus
Bouboui virus
Edge Hill virus
Jugra virus
Sapoya virus
Sepik virus
Uganda S virus
Wesselsbron virus
Yellow fever virus

Note: We are ahead of the curve, WHO/CDC which of these mosquitoe borne viruses will be next? How about Uganda S or Kedougou virus? Kokobera virus (ATCC® VR-379™) sounds strange enough? Nope, thats from Australia, it needs to come from Africa to make it scary enough.

Truth-out: Florida Dengue Fever Outbreak Leads Back to CIA and Army Experiments

http://truth-out.org/archive/component/k2/item/90808:florida-dengue-fever-outbreak-leads-back-to-cia-and-army-experiments
Wednesday, 21 July 2010 12:08
By HP Albarelli Jr and Zoe Martell

Unknown to most Americans is that dengue fever has been the intense focus of US Army and CIA biological warfare researchers for over 50 years. Ed Regis notes in his excellent history of Fort Detrick, “The Biology of Doom,” that as early as 1942 leading biochemists at the installation placed dengue fever on a long list for serious consideration as a possible weapon. In the early 1950s, Fort Detrick, in partnership with the CIA, launched a multi-million dollar research program under which dengue fever and several addition exotic diseases were studied for use in offensive biological warfare attacks. Assumably, because the virus is generally not lethal, program planners viewed it primarily as an incapacitant. Reads one CIA Project Artichoke document: “Not all viruses have to be lethal … the objective includes those that act as short-term and long-term incapacitants.”

Applied Biosystems 3400 DNA Synthesizer

Link to PDF

Applied Biosystems 3400 DNA Synthesizer

The Applied Biosystems 3400 DNA Synthesizer is a versatile, four-column,
benchtop instrument designed for 40-nmol, 200-nmol, and 1-μmol synthesis
scales. Simultaneous synthesis and cleavage of four oligonucleotides (25-
mer at 40- or 200-nmol scales) requires approximately four hours

DNA Purity and Quality Established phosphoramidite chemistry
produces DNA that is pure and chemically authentic. The instrument routinely
synthesizes oligonucleotides with average coupling yields > 98% as measured by
HPLC analysis. A simple desalting of crude deprotected oligonucleotides is adequate for most applications

Applied Biosystems 394 DNA/RNA Synthesizer

The Applied BioSystems 394 DNA/RNA Synthesizer, automates all steps of single stranded oligonucleotide synthesis. When used as a system including Applied Biosystems reagents and columns, these instruments produce the highest quality synthetic DNA currently attainable while minimizing synthesis time and cost.

Applied Biosystems 394 DNA/RNA Synthesizer
Applied Biosystems 394 DNA/RNA Synthesizer

http://www.labx.com/item/applied-biosystems-394-dna-rna-synthesizer/LV34222695

ABI 3400 DNA/ RNA Synthesizer

eABI 3400 DNA/ RNA Synthesizer
Applied Biosystems 3400 DNA / RNA Synthesizer
The Applied Biosystems 3400 DNA Synthesizer is a fully programmable instrument that provides four-column simultaneous synthesis, and features automatic base dilution and analysis of coupling efficiency. Fast cycle times, online cleavage, and proven phosphoramidite chemistry result in exceptionally pure oligonucleotides. Versatile, dependable, and easy to use, the 3400 synthesizer is a compact, bench-top instrument designed for 40 nmol, 200 nmol, and 1 µmol synthesis scales. Simultaneous synthesis and cleavage of four oligonucleotides (25- mer at 40- or 200-nmol scales) requires approximately four hours.

http://www.bluelionbio.com/labequip.phtml?lab_equip_id=599&mode=detail&category_id=20&search_text=

Note: The technology is very CHEAP for a nation state or corporation. The above models can be bought for under $50K. There are DIY efforts to make this even cheaper, think along the lines of 3D-printing. This clearly shows the routine competency regarding DNA/RNA synthesis and tinkering.

Oxitec (GM Mosqitoes) – Our Team

Oxitec Ltd. was founded in 2002 and is based in Oxford, United Kingdom. As of September 8, 2015, Oxitec Ltd. operates as a subsidiary of Intrexon Corporation.

http://www.oxitec.com/who-we-are/our-team/

Hadyn Parry, Chief Executive Officer

Hadyn ParryHadyn has an extensive background in the Life Science sector. During his fifteen-year career at Zeneca/Syngenta he held various positions, including General Manager of Zeneca Plant Sciences and European Director and Global Head of R&D for Advanta, one of the world’s largest seed companies. More recently he was CEO of MNL Pharmaceuticals, a company that was focused on pioneering a novel approach in immunology. Hadyn is also Chairman of Help For Heroes, a charity founded in 2007 to support wounded British soldiers.

Simon Warner, Chief Scientific Officer

Simon WarnerSimon has eighteen years of global commercial experience in biotechnology R&D in various roles at Syngenta in the United Kingdom and the United States, leading collaborative programs and delivering biotechnology products in crops for feed and fuel. Additionally, whilst at Syngenta he also worked as the R&D lead on technology acquisition on various agreements. Immediately prior to joining Oxitec, he was Senior Director of Research and Development Programs at Sapphire Energy, a start-up making algae based fuel, based in San Diego, California. Simon has a BSc in biochemistry from UCL and PhD in plant molecular biology from the University of Leicester.

Bill Fleming, Chief Financial Officer

Bill Fleming Bill joins us from Bayer Healthcare having held senior finance positions in Europe and the USA. He has a law degree from Cambridge University and is a qualified ACMA. Previously, Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics.

Camilla Beech, Regulatory Affairs Manager

Camilla BeechCamilla has extensive international experience in the regulation of biotechnology products and crops. She obtained commercial food approval in the UK for the first GM crop in Europe, and obtained registrations for numerous biotechnology crops in Africa, Asia and the Americas. She advised the Humanitarian Board for Golden Rice on regulatory matters (1997 to 2004), and was a member of both US (BIO) and European Inter-industry groups (EUROPABIO) on The Cartagena Biosafety Protocol, Convention on Biological Diversity and Plant made Pharmaceuticals. Her most recent post was International Regulatory Manager for Syngenta Biotechnology Inc., based in San Diego, California.

Glen Slade, Head of Business Development

Glen SladeGlen has worked in agribusiness since 1998 when he joined Zeneca Agrochemicals as Head of Strategy. There he championed the role of biotechnology in integrated crop solutions, leading to the merger that formed Syngenta. He then worked in independent consulting roles addressing high profile marketing and strategy projects for Syngenta, Arysta and other agribusiness firms. In parallel to this work, Glen set up and ran two IT-related companies. He has a degree from Cambridge University and an MBA from Insead.

Hadyn Parry: Re-engineering mosquitos to fight disease

Published on 3 Jan 2013
In a single year, there are 200-300 million cases of malaria and 50-100 million cases of dengue fever worldwide. So: Why haven’t we found a way to effectively kill mosquitoes yet? Hadyn Parry presents a fascinating solution: genetically engineering male mosquitoes to make them sterile, and releasing the insects into the wild, to cut down on disease-carrying species.
TED Talk Link

Transcript:
9:27
“And that’s exactly where we are. So this is technology that was developed in Oxford University a few years ago. The company itself, Oxitec, we’ve been working for the last 10 years, very much on a sort of similar development pathway that you’d get with a pharmaceutical company. So about 10 years of internal evaluation, testing, to get this to a state where we think it’s actually ready. And then we’ve gone out into the big outdoors, always with local community consent, always with the necessary permits. So we’ve done field trials now in the Cayman Islands, a small one in Malaysia, and two more now in Brazil…

We can produce them, in a space a bit more than this red carpet, I can produce about 20 million a week. We can transport them around the world. It’s not very expensive, because it’s a coffee cup — something the size of a coffee cup will hold about three million eggs. So freight costs aren’t our biggest problem. (Laughter) So we’ve got that. You could call it a mosquito factory. And for Brazil, where we’ve been doing some trials, the Brazilian government themselves have now built their own mosquito factory, far bigger than ours, and we’ll use that for scaling up in Brazil.

GM mosquito expansion announced

http://www.bbc.co.uk/news/science-environment-35353768
A company producing GM mosquitoes says it is to open a new factory in Brazil as it expand its operations.
Small-scale studies in parts of Brazil, Panama and the Cayman Islands suggest engineered sterile mosquitoes can reduce wild insect populations by more than 90% when released into the wild.
Intrexon said the facility in Piraciciba, São Paulo, will be able to protect 300,000 people.
Aedes aegypti mosquitoes carry three viruses – Dengue, Zika and Chikungunya.
The studies were carried out by the only company currently trialling GM insects, Oxitec, based in Abingdon, Oxfordshire.
Oxitec, which was spun out from the University of Oxford, was bought by US company Intrexon for $160m (£106m) in August last year.
Oxitec CEO Hadyn Parry said: ” As the principal source for the fastest growing vector-borne infection in the world in Dengue fever, as well as the increasingly challenging Zika virus, controlling the Aedes aegypti population provides the best defence against these serious diseases for which there are no cures.”

Note: “…fastest growing vector infection”? Captain Parry of corporate pirate ship Oxitec, states he will find the solution now we have a problem. Any shares for sale Captain Parry? Still private, ground floor oppurtunity investor, climb aboard.

Synthetic virology | Andrew Hessel | TEDxDanubia

Published on May 26, 2014
Andrew Hessel designs synthetic viruses and uses the latest 3D printing technology to create medicine that is designed individually for a single patient. The promise here is that once he succeeds to design a synthetic virus that is able to penetrate the medicine throughout the body of the patient, he can scale the solution and present the world an almost free and much more capable medicine against cancer.

Synthetic biology…it’s genetic engineering done with digital tools.

…You do all you genetic design on a computer and then there’s this brilliant machine called a synthesiser that prints out that DNA.
You put that DNA into a cell and you can make it do damn near anything fuel, drugs, enzymes, biochemicals
…cancer-breaking virus…actually using cancer cells to make the drug that kills them…”

Note: The ability to engineer or manipulate bacteria and viruses are boastfully stated as common practise, as well as being relatively cheap.
You can see how GcMAF totally destroys this embroynic pharma niche. A natural safe method undermines the custom gene-splicers.

Dr. Robert Rowen, MD Describes Benefits Of Ozone Therapy

Uploaded on 3 Oct 2007

Dr. Rowen understands when to use allopathic, conventional, alternative, complimentary and oxidative medicine to help his patients heal and experience optimal health. Robert Rowen, MD, Editor Second Opinion Newsletter ozone, ultraviolet blood irradiation, hyperbaric oxygen valuable for healing and battle against microbial infections.

http://healthydoctors.com/
http://robert-rowen-md.com/